In acute myeloid leukemia and breast cancer cells 46, low doses of DNMTis in combination with PARPis have been shown to increase the retention of PARP1 on chromatin through the induction of PARP1-DNA adducts and the covalent binding of DNMTs. Here, PARP1 is linked to breast carcinoma.